Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.47 |
| ▸ | JAK1 | P23458 | 3/20 | 0.47 |
| ▸ | TYK2 | P29597 | 2/20 | 0.47 |
| ▸ | JAK3 | P52333 | 2/20 | 0.47 |
| ▸ | BCL9 | O00512 | 6/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 6/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4475037 | 0.82 | BCL9 (0.47) | JAK2JAK1TYK2JAK3BCL9 | |
| SCHEMBL14530355 | 0.80 | JAK2 (0.50) | JAK2JAK1TYK2JAK3BCL9 | |
| SCHEMBL8427778 | 0.80 | JAK2 (0.50) | JAK2JAK1TYK2JAK3BCL9 | |
| SCHEMBL4475659 | 0.79 | JAK2 (0.48) | JAK2JAK1TYK2JAK3BCL9 | |
| SCHEMBL14530393 | 0.78 | JAK2 (0.47) | JAK2JAK1TYK2JAK3BCL9 | |
| SCHEMBL2063481 | 0.77 | USP30 (0.58) | USP30PDE4BMAPK1ITGB3ITGA2B | |
| SCHEMBL26602429 | 0.77 | USP30 (0.53) | JAK2JAK1TYK2JAK3BCL9 | |
| SCHEMBL15669949 | 0.77 | USP30 (0.53) | JAK2JAK1TYK2JAK3BCL9 | |
| SCHEMBL2063483 | 0.77 | USP30 (0.58) | USP30PDE4BMAPK1ITGB3ITGA2B | |
| SCHEMBL6128873 | 0.77 | USP30 (0.58) | USP30PDE4BMAPK1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576085-B2 | Imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2009-08-18 | — | — | US | disclosed |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | JAK2 143/4885JAK1 110/4885TYK2 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.